Filing identity and reporting period
Important: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended June 30, 2021—not a filing identified as Oruka Therapeutics, Inc. The summary below reflects the filing text provided.
ARCA is a clinical-stage biopharmaceutical company with no product revenue to date. Its lead programs are rNAPc2 (AB201), being studied for hospitalized COVID-19 patients, and Gencaro, under development for atrial fibrillation in certain heart-failure patients. The filing reports the three and six months ended June 30, 2021, compared with the same 2020 periods.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | No revenue | No revenue | No revenue | No revenue |
| Research and development expense | $3.577 million | $0.372 million | $6.453 million | $0.737 million |
| General and administrative expense | $1.260 million | $0.938 million | $2.486 million | $1.913 million |
| Net loss | $4.834 million | $1.302 million | $8.934 million | $2.622 million |
| Net loss per share, basic and diluted | $0.34 | $0.73 | $0.67 | $1.55 |
| Net cash used in operating activities | Not separately stated for the quarter | $8.945 million | $2.728 million |
At June 30, 2021, cash and cash equivalents were $63.197 million, versus $49.071 million at December 31, 2020. Total assets were $65.338 million and total liabilities $4.130 million; stockholders’ equity was $61.208 million. Liabilities included $0.522 million of operating lease obligations. The filing reports no interest expense in the first half of 2021 and does not disclose material interest-bearing debt.
Cash increased by $14.126 million in the first half, principally due to $23.093 million of net financing cash flows, largely from at-the-market stock sales, offset by operating cash use. The company issued 4,861,993 shares under its equity sales agreement for approximately $23.3 million in net proceeds during the first half. It reported $50 million available under the amended offering prospectus.
Changes versus the prior comparable period
- Q2 R&D expense rose by approximately $3.2 million; first-half R&D increased by approximately $5.7 million. The filing attributes most of the rise to rNAPc2 clinical-trial and manufacturing-process-development costs, plus outside services.
- First-half operating cash use increased by $6.2 million year over year, reflecting a higher net loss and changes in operating assets and liabilities.
- First-half net loss increased to $8.934 million from $2.622 million. The reported loss per share was lower than in 2020, while weighted-average shares increased substantially following equity issuance.
Outlook, developments, and risks
- Management said available cash was expected to fund operations through the end of fiscal 2022, including the rNAPc2 Phase 2b trial. A Phase 3 rNAPc2 trial or the Gencaro PRECISION-AF Phase 3 trial would likely require additional financing.
- ARCA increased the ASPEN-COVID-19 Phase 2b target enrollment from 100 to approximately 160 patients in July 2021 and expected topline data in Q4 2021. Trial timing depends on enrollment, results, FDA guidance, and drug supply.
- PRECISION-AF remained on hold, pending additional financing and improvement in the pandemic sufficient to support patient recruitment. The filing also describes Gencaro’s development timing as dependent on financing and pandemic conditions.
- In July 2021, ARCA obtained exclusive worldwide patent rights from the University Medical Center Mainz relating to rNAPc2. Upfront and potential milestone obligations could total approximately €1.6 million, with low-single-digit royalties if the product is approved and commercialized.
- Key risks include clinical-trial failure or delays, patient enrollment and supply constraints, dependence on third parties, the need for substantial additional capital or a strategic transaction, potential dilution from further equity sales, Nasdaq listing requirements, and uncertainty about future operations. The filing states that the financial statements use the going-concern basis and notes uncertainty in future years tied to additional funding needs.
- Management reported disclosure controls and procedures were effective at a reasonable level of assurance and no material change in internal control over financial reporting during the quarter. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer: this source is an ARCA biopharma filing, not an Oruka Therapeutics filing.
- Check subsequent disclosures for ASPEN-COVID-19 enrollment, topline results, and any Phase 3 decision or financing.
- Verify current cash runway, cash use, and the status and remaining capacity of the equity sales agreement.
- Track the financing and restart plans for PRECISION-AF and any Gencaro Phase 3 trial.
- Review the Mainz patent agreement’s final payment, milestone, and royalty terms and any later updates.